The report from the Health Care Cost Institute (HCCI) examined claims for people with multiple sclerosis (MS) from 2009 to 2015 covered by individual market, employer-sponsored or Medicare Advantage plans. It found total spending per MS patient rose from around $23,900 to $39,628 by 2015. During the same time period, the share of spending spent towards injectable and oral disease modifying therapies (DMTs) rose from 39 percent to 53 percent.